Illumina acquires DNA sequencer Pacific Bio; deal terminated
Illumina Inc. acquired "long-read" DNA sequencing company Pacific Biosciences of California Inc. for $8 per share in cash (89% premium to the prior 10-day trading average), or a fully diluted equity value of $1.2bn (taking into account cash and debt enterprise value of $1.1bn; sales multiple of 12.7x) .
- Research, Analytical Equipment & Supplies
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.